Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

doi:10.1038/tpj.2017.39

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

The pharmacogenomics journal - 22 May 2018

Spraggs C F, Parham L R, Briley L P, Warren L, Williams L S, Fraser D J, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski J A, Crescenzo R, Armour A, Perez E, Piccart M

Abstract excerpt

HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cancer (adjuvant lapatinib and/or trastuzumab treatment optimisation). HLA-DRB1*07:01 carriage was associated with serum alanine aminotransferase (ALT) elevations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemical and Drug Induced Liver Injury

Share to HLA-DRB1 Chains

Share to Lapatinib

Share to Liver

Share to Neoplasm Staging

Share to Taxoids

Share to Trastuzumab

Source

Open in PubMed

Identifiers

PMID: 28786423
DOI: 10.1038/tpj.2017.39

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.PMID 28786423Read ↗

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.Semantic proximity Read ↗

Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.Semantic proximity Read ↗

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.Semantic proximity Read ↗

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.Semantic proximity Read ↗

Genetic Characterization to Improve Interpretation and Clinical Management of Hepatotoxicity Caused by Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.Semantic proximity Read ↗

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.Semantic proximity Read ↗

Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.